Hematology · Myeloproliferative Neoplasms
The facts most likely to be tested
Press 1–5 to rate · ↑↓ to navigate
The hallmark genetic abnormality is the Philadelphia chromosome, a t(9;22) translocation resulting in the BCR-ABL1 fusion gene.
The BCR-ABL1 fusion gene encodes a constitutively active tyrosine kinase that drives uncontrolled myeloid cell proliferation.
Peripheral blood smears characteristically show a leukocytosis with a left shift, featuring a full spectrum of myeloid cells including myelocytes, metamyelocytes, and bands.
The leukocyte alkaline phosphatase (LAP) score is characteristically low in CML, helping to distinguish it from a leukemoid reaction.
Patients often present with splenomegaly, which may cause early satiety or left upper quadrant pain.
First-line treatment for chronic-phase CML is a BCR-ABL1 tyrosine kinase inhibitor (TKI). Per current NCCN guidance, imatinib is preferred (Category 1) for low-risk disease (by Sokal/ELTS score), while second-generation TKIs (dasatinib, nilotinib, bosutinib) or asciminib are preferred (Category 1) regardless of risk, including intermediate/high-risk disease.
Progression to blast crisis is defined by the presence of ≥20% blasts in the blood or bone marrow, signaling a transition to an acute leukemia-like clinical course.
Vignette unlocked
A 52-year-old male presents to the clinic complaining of early satiety and a dragging sensation in his left upper quadrant. Physical examination reveals a palpable spleen extending 5 cm below the costal margin. Laboratory studies demonstrate a white blood cell count of 115,000/µL with a differential showing a predominance of myelocytes and metamyelocytes. The leukocyte alkaline phosphatase score is low. Cytogenetic analysis confirms the presence of the t(9;22) translocation.
What is the most appropriate first-line pharmacologic therapy for this patient?
Imatinib
The patient's presentation of splenomegaly, extreme leukocytosis with a left shift, and the presence of the Philadelphia chromosome is diagnostic for CML, which is treated with a BCR-ABL1 tyrosine kinase inhibitor; imatinib is a standard first-line option, particularly for lower-risk disease, though current risk-stratified NCCN guidance also supports second-generation TKIs (dasatinib, nilotinib, bosutinib) or asciminib as preferred first-line options.
Full handout
High yield triage
Etiology / Epidemiology
Myeloproliferative neoplasm driven by the Philadelphia chromosome (t(9;22)). Median age of onset is 50-60 years.
Clinical Manifestations
Often asymptomatic; presents with splenomegaly, fatigue, and leukocytosis with a left shift.
Diagnosis
BCR-ABL1 fusion gene via FISH or RT-PCR is the gold standard. Bone marrow shows hypercellularity.
Treatment
A BCR-ABL1 tyrosine kinase inhibitor is first-line; imatinib for low-risk disease, a 2nd-generation TKI (dasatinib/nilotinib/bosutinib) or asciminib preferred for intermediate/high-risk. All BCR-ABL1 TKIs are contraindicated in pregnancy.
Prognosis
Progression to blast crisis (≥20% blasts) signifies transformation to acute leukemia.
Full handout
Epidemiology & Etiology
CML accounts for approximately 15% of adult leukemias, most commonly diagnosed in older adults (peak incidence ages 65-74; median age of diagnosis in the mid-to-upper 60s in the US). The primary driver is the reciprocal translocation between chromosomes 9 and 22, known as the Philadelphia chromosome. Ionizing radiation is the only well-established environmental risk factor.
Pertinent Anatomy
The disease originates in the hematopoietic stem cell within the bone marrow. Massive expansion of myeloid cells leads to secondary extramedullary hematopoiesis, primarily in the spleen and liver.
Pathophysiology
The t(9;22) translocation creates the BCR-ABL1 fusion gene, which encodes a constitutively active tyrosine kinase. This protein promotes uncontrolled proliferation of myeloid cells and inhibits apoptosis. The disease progresses from chronic phase to blast phase (>=20% blasts); some classification systems (ICC 2022) retain an intermediate accelerated phase, though WHO 2022 and the 2025 ELN recommendations favor a two-phase (chronic/blast) model.
Clinical Manifestations
Patients are frequently diagnosed incidentally via routine CBC showing leukocytosis. Classic symptoms include fatigue, weight loss, and early satiety due to massive splenomegaly. Red flags include fever, bone pain, and bleeding, which suggest progression to the accelerated phase or blast crisis.
Diagnosis
The gold standard for diagnosis is the detection of the BCR-ABL1 fusion gene via FISH or RT-PCR. Peripheral blood smear reveals marked leukocytosis with a left shift and a full spectrum of myeloid cells (myelocytes, metamyelocytes). Bone marrow biopsy is required to confirm hypercellularity and rule out acute transformation.
Treatment
First-line treatment is a BCR-ABL1 tyrosine kinase inhibitor (TKI): per NCCN v1.2026, imatinib is Category-1 preferred for low-risk disease, while second-generation TKIs (dasatinib, nilotinib, bosutinib) and the allosteric inhibitor asciminib are Category-1 preferred regardless of risk and are also used for resistance/intolerance. All BCR-ABL1 TKIs, not just imatinib, are teratogenic and require effective contraception. Testing for the T315I resistance mutation is indicated on TKI failure; ponatinib (or asciminib) is active against T315I. Allogeneic stem cell transplant is reserved for patients who fail TKI therapy.
Prognosis
With TKI therapy, the 10-year survival rate exceeds 80-90%. Monitoring requires serial BCR-ABL1 transcript levels to assess molecular response. Failure to achieve milestones leads to blast crisis, which carries a very poor prognosis.
Differential Diagnosis
Leukemoid reaction: LAP score is high (low in CML)
Polycythemia vera: JAK2 mutation positive
Essential thrombocythemia: Platelets >450k without BCR-ABL1
Myelofibrosis: Bone marrow fibrosis and teardrop cells
Acute Myeloid Leukemia: ≥20% blasts at presentation